Production (Stage)
Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -75.67% | -60.62% | -42.32% | -15.60% | 4.74% |
| Total Other Revenue | -22.99% | -9.43% | 6.54% | 15.99% | 23.14% |
| Total Revenue | -67.34% | -52.41% | -34.36% | -10.85% | 7.27% |
| Cost of Revenue | -7.18% | -6.15% | -5.00% | 3.92% | 11.37% |
| Gross Profit | -668.29% | -10,227.66% | -298.45% | -1,017.05% | -21.56% |
| SG&A Expenses | 7.84% | 3.65% | -0.35% | -7.97% | -16.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.48% | -3.72% | -3.84% | 0.64% | 2.86% |
| Operating Income | -306.86% | -146.66% | -62.26% | -32.45% | 14.26% |
| Income Before Tax | -552.82% | -25.72% | 41.95% | 63.00% | 85.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -552.82% | -25.72% | 41.95% | 63.00% | 85.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -552.82% | -25.62% | 42.01% | 63.06% | 85.98% |
| EBIT | -306.86% | -146.66% | -62.26% | -32.45% | 14.26% |
| EBITDA | -488.69% | -229.22% | -106.95% | -58.85% | 19.00% |
| EPS Basic | -549.90% | -23.58% | 42.94% | 63.64% | 86.18% |
| Normalized Basic EPS | -549.92% | -174.24% | -49.87% | -8.31% | 51.23% |
| EPS Diluted | -542.55% | -23.40% | 42.87% | 63.48% | 86.02% |
| Normalized Diluted EPS | -541.84% | -172.53% | -49.24% | -7.82% | 51.32% |
| Average Basic Shares Outstanding | 0.74% | 0.88% | 1.01% | 1.02% | 1.02% |
| Average Diluted Shares Outstanding | -2.01% | -1.89% | -1.77% | 0.99% | 2.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |